Fuan Pharmaceutical: Three drugs are proposed to be selected for the twelfth national drug centralized procurement.

Fuan Pharmaceutical announced that its wholly-owned subsidiaries Tianheng Pharmaceutical, Zhichu Pharmaceutical, and Renmin Pharmaceutical will participate in the bidding for the twelfth batch of national centralized drug procurement on July 31, 2026. Three products, namely Nicardipine Hydrochloride Injection, Teicoplanin for Injection, and Isavuconazole Sulfate for Injection, are expected to be selected. The procurement period will commence from the date the selection results are implemented and continue until December 31, 2029. It is noted that the aforementioned anticipated selected products are projected to have no production and sales revenue in 2025.